FN2 Earnings Intelligence
Zimmer Biomet Holdings, Inc. financials
Zimmer Biomet Holdings, Inc. (ZBH) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $478.5 | $375.7 | $415.8 | $525.5 | $591.9 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $7,836.2 | $6,939.9 | $7,394.2 | $7,678.6 | $8,231.5 | $8,549.3 | $8,850 |
| % Growth | 11.6% | -11.4% | 6.5% | 3.8% | 7.2% | 3.9% | 3.5% |
| Gross Profit | $5,495.2 | $4,920.4 | $5,310.4 | $5,487.4 | $5,737.8 | - | - |
| % Margin | 70.1% | 70.9% | 71.8% | 71.5% | 69.7% | - | - |
| EBITDA | $1,847.5 | $1,622.7 | $2,229.4 | $2,282 | $2,191.9 | - | - |
| % Margin | 23.6% | 23.4% | 30.2% | 29.7% | 26.6% | - | - |
| Net Income | $401.6 | $231.4 | $1,024 | $903.8 | $705.1 | - | - |
| % Margin | 5.1% | 3.3% | 13.8% | 11.8% | 8.6% | - | - |
| Diluted EPS | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 | $8.49 | $9.01 |
| % Growth | 385.1% | -42.4% | 343.6% | -9.2% | -19.9% | 139.1% | 6.1% |
| Operating Cash Flow | $1,499.2 | $1,356.2 | $1,581.6 | $1,499.4 | $1,697.1 | - | - |
| CapEx | $172 | $187.9 | $291.1 | $203.8 | $224.5 | - | - |
| Free Cash Flow | $1,327.2 | $1,168.3 | $1,290.5 | $1,295.6 | $1,472.6 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $7,836.2 | $6,939.9 | $7,394.2 | $7,678.6 | $8,231.5 | $8,549.3 | $8,850 |
| Gross Profit | $5,495.2 | $4,920.4 | $5,310.4 | $5,487.4 | $5,737.8 | - | - |
| EBITDA | $1,847.5 | $1,622.7 | $2,229.4 | $2,282 | $2,191.9 | - | - |
| Net Income | $401.6 | $231.4 | $1,024 | $903.8 | $705.1 | - | - |
| Diluted EPS | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 | $8.49 | $9.01 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $478.5 | $375.7 | $415.8 | $525.5 | $591.9 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $5,463.7 | $5,152.2 | $4,867.9 | $5,341.6 | $6,932 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1,499.2 | $1,356.2 | $1,581.6 | $1,499.4 | $1,697.1 |
| Capital Expenditure | $172 | $187.9 | $291.1 | $203.8 | $224.5 |
| Free Cash Flow | $1,327.2 | $1,168.3 | $1,290.5 | $1,295.6 | $1,472.6 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 11.6% | -11.4% | 6.5% | 3.8% | 7.2% |
| Gross Margin | 70.1% | 70.9% | 71.8% | 71.5% | 69.7% |
| EBITDA Margin | 23.6% | 23.4% | 30.2% | 29.7% | 26.6% |
| Net Margin | 5.1% | 3.3% | 13.8% | 11.8% | 8.6% |
| FCF Margin | 16.9% | 16.8% | 17.5% | 16.9% | 17.9% |
| Diluted EPS Growth | 385.1% | -42.4% | 343.6% | -9.2% | -19.9% |